An interventional study of Yerba mate tea and Control drink in Cardiovascular Risk and Hypercholerolemia, sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición. Completed at 1 site in Spain. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-22.
Sponsored by Instituto de Ciencia y Tecnología de Alimentos y Nutrición · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Inflammation with a site in Spain — 32 open to participants now, 41 under way, 2 of them phase 3. Inflammation · Spain.
Among the 149 studies in Inflammation with a site in Spain, this one is the 75th largest by enrollment of the 114 interventional ones that give a count, is one of 10 that started in 2012, is one of 71 with no phase, and was the 119th registered.
3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →32 of the 149 studies in Inflammation with a site in Spain are open now. Recruiting first, the newest first:
Institut Investigacio Sanitaria Pere Virgili · Sites in Spain
Ages 45–75
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Sites in Spain
Ages 18–65 · Healthy volunteers
Fundació Eurecat · Sites in Spain
Ages 40–70
University of Seville · Sites in Spain
Ages 35–36 · Healthy volunteers
Abcentra · Sites in Spain, United States, Czechia and 6 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 22 · Phase 3 20 · Phase 4 5
First in 2001; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 50 across 2,586 interventional studies indexed under Inflammation.
Median enrollment 68 across the 114 interventional studies, 100 across the 35 observational. Of the 95 that completed or were terminated, 16 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 149 have an industry lead sponsor. The 10 most frequent:
Instituto de Ciencia y Tecnología de Alimentos y Nutrición is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Instituto de Ciencia y Tecnología de Alimentos y Nutrición has 3 studies filed under Inflammation — fewer than ten, so there is no comparison to draw.
16 of the studies in Inflammation with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT07066033Esther NovaA Study of the Intestinal Microbiota in Children and Adolescents With Eating Disorders. A Perspective From Psychoneuroimmunology | 2026-12 |
| NCT07894562José Enrique de la Rubia Ortí, PhEfficacy of MAGNESIO TOTAL on Sleep Quality and Quality of Life in Adults | 2026-12-16 |
| NCT06245616Spanish National Research CouncilAttenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil | 2026-12-30 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 149 studies in Inflammation with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if consuming a beverage prepared with yerba mate leaves helps to improve blood lipid levels in persons at high cardiovascular risk. It will also learn about the effects of this beverage, widely consumed in South America, on other cardiometabolic biomarkers like blood glucose levels, inflammation, or weight control. The main questions it aims to answer are:
Does daily consumption of a yerba mate tea reduce the blood lipid levels in hypercholesterolemic persons? May healthy persons also benefit from the consumption of yerba mate tea?
Researchers will compare yerba mate to a control drink (isotonic drink or water, free of polyphenols and caffeine) to see if yerba mate tea helps to reduce blood cholesterol in hypercholesterolemic persons.
Participants will:
Drink 3 cups of yerba mate tea or an isotonic drink every day for 2 months, then change to the other drink during another 2 months.
Visit the clinic at the beginning and end of each 2-month period for checkups and tests Refraing from consuming coffee and some foods during the study. Complete a dietary questionnaire during 3 days before each visit to the clinic.
This is a randomized, crossover, control study in healthy and hypercholesterolemic free-living to assess the effect of yerba mate on different outcomes related to cardiovascular health.
After a 2-week run-in period, participants will be randomly allocated to the first 8-weeks intervention with yerba mate or the control drink. After a 3-week wash-out, they will change to consume during 8 weeks the other drink.
A nurse will collect a fasting blood sample at the beginning and end of each intervention stage. Blood pressure and anthropometric parameters will be measured. A 72-h dietary record will be completed by participants before each visit to the Human Nutrition Unit (HNU) at the Institute of Food Science, Technology and Nutrition (ICTAN-CSIC).
During the study, participants will refrain from consuming coffee, cocoa, tea, and caffeine-containing drinks. Other foods rich in certain polyphenols (i.e. hydroxycinnamic acids) will also be restricted.
Blood samples will be used to measure different biomarkers of relevance in cardiometabolic health, as listed in the Outcomes section.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Consumption of three cups of a yerba mate tea per day
Dietary Supplement: Yerba mate tea
Consuming water or an isotonic drink, free of polyphenols or caffeine.
Dietary Supplement: Control drink
Consumption of three cups per day of a beverage prepared with yerba mate
Consumption of water or an isotonic drink, free of polyphenols or caffeine. Abstention of consuming coffee.
Blood lipids
Change in blood levels of total cholesterol or LDL-cholesterol or VLDL-cholesterol or HDL-cholesterol or triglycerides or phospholipids at the end of the intervention with yerba mate
Time frame: From enrollment to the end of each treatment at 8 weeks
Blood pressure
Changes in blood pressure at the end of the intervention with yerba mate.
Time frame: From enrollment to the end of each treatment at 8 weeks
Inflammatory cytokines
Change in the levels of C-reactive protein (CRP), or pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-a), or interferon gamma (IFN-g), interleukin (IL)-1beta (IL-1b), or IL-2, or IL-5, or IL-6, or IL-7, or IL-8, or IL-12 or IL-13)) or anti-inflammatory cytokines IL-4 or IL-10 at the end of the intervention with yerba mate
Time frame: From enrollment to the end of each treatment at 8 weeks
Fasting blood glucose
Change of fasting blood glucose levels at the end of the intervention with yerba mate
Time frame: From enrollment to the end of each treatment at 8 weeks
Fasting blood insulin
Change of fasting insulin levels at the end of intervention with yerba mate
Time frame: From enrollment to the end of each treatment at 8 weeks
Insulin resistance
Change in homeostasis model assessment (HOMA) of insulin resistance (HOMA-IR) at the end of intervention with yerba mate
Time frame: From enrollment to the end of each treatment at 8 weeks
Insulin sensitivity
Change in quantitative insulin levels sensitivity check index (QUICKI) at the end of the intervention with yerba mate. Higher score in QUICKI means a better outcome compared to initial values.
Time frame: From enrollment to the end of each treatment at 8 weeks
Hormones, incretins and adipokines levels
Changes in serum levels of C peptide or glucagon or glucagon inhibitory peptide (GIP) or glucagon-like peptide type 1 (GLP-1) or ghrelin or leptin or resistin or plasminogen activator inhibitor type 1 (PAI-1) or visfatin at the end of the intervention with yerba mate.
Time frame: From enrollment to the end of each treatment at 8 weeks
Cytokines, chemokines and cell-adherence molecules levels
Changes in serum levels of granulocyte (G-CSF) or granulocyte/macrophague (GM-CSF) colony-stimulating factors, or monocyte-chemoattractant protein-1 (MCP-1) or macrophage inflammatory protein-1beta (MIP-1b) or vascular (VCAM-1) or intracellular (ICAM-1) adhesion molecules at the end of the intervention with yerba mate.
Time frame: From enrollment to the end of each treatment at 8 weeks
Liver function
No changes in serum levels of alanin transferase (ALAT), or aspartate transferase (ASAT) at the end of the intervention with yerba mate.
Time frame: From enrollment to the end of each treatment at 8 weeks
Anthropometry
Changes in body weight or body fat percentage or body circunferences (wais, or hip, or thigh, or brachial) or skinfolds (tricipital or subscapular) at the end of the intervention with yerba mate.
Time frame: From enrollment to the end of each treatment at 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2012 to primary completion in Jul 2013, 18 months.
Of 882 non-industry interventional studies with no phase under Inflammation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 18 months is close to that.
Counting every sponsor, half of 929 studies reached it within 17 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Ciencia y Tecnología de Alimentos y Nutrición